These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10838972)

  • 1. Limitations of ferritin as a marker of anemia in end stage renal disease.
    Dennison HA
    ANNA J; 1999 Aug; 26(4):409-14; quiz 419-20. PubMed ID: 10838972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
    Easom A
    Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron therapy for renal anemia: how much needed, how much harmful?
    Hörl WH
    Pediatr Nephrol; 2007 Apr; 22(4):480-9. PubMed ID: 17206511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing iron status: beyond serum ferritin and transferrin saturation.
    Wish JB
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron management in ESRD and the role of the nephrology nurse.
    Robbins KC; Senger JM; Kerhulas S; Fishbane S
    ANNA J; 1997 Apr; 24(2):265-72; quiz 273-4. PubMed ID: 9180431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients.
    Peacock E; Lindenfeld SM
    ANNA J; 1999 Jun; 26(3):337-43. PubMed ID: 10633605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection and inflammation in dialysis patients: impact on laboratory parameters and anemia. Case study of the anemic patient.
    Szymanski N
    Nephrol Nurs J; 2001 Jun; 28(3):337-40. PubMed ID: 12143455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of ferritin for optimizing anemia therapy in chronic kidney disease.
    Nakanishi T; Kuragano T; Nanami M; Otaki Y; Nonoguchi H; Hasuike Y
    Am J Nephrol; 2010; 32(5):439-46. PubMed ID: 20881381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating traditional iron measures and exploring new options for patients on hemodialysis.
    Petroff S
    Nephrol Nurs J; 2005; 32(1):65-73; quiz 74-5. PubMed ID: 15787086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients.
    Rocha LA; Barreto DV; Barreto FC; Dias CB; Moysés R; Silva MR; Moura LA; Draibe SA; Jorgetti V; Carvalho AB; Canziani ME
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):105-9. PubMed ID: 18842949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
    Dukkipati R; Kalantar-Zadeh K
    Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Issues related to iron replacement in dialyzed patients].
    Kessler M
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S266-73. PubMed ID: 17373269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of iron deficiency to anemia in chronic renal failure.
    Gupta M; Kannan M; Gupta S; Saxena R
    Indian J Pathol Microbiol; 2003 Oct; 46(4):563-4. PubMed ID: 15025343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum transferrin receptor in children: usefulness for determinating the nature of anemia in infection.
    Angeles Vázquez López M; Molinos FL; Carmona ML; Morales AC; Muñoz Vico FJ; Muñoz JL; Muñoz Hoyos A
    J Pediatr Hematol Oncol; 2006 Dec; 28(12):809-15. PubMed ID: 17164650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transferrin receptor assay and zinc protoporphyrin as markers of iron-deficient erythropoiesis in end-stage renal disease patients.
    Baldus M; Walter H; Thies K; Anders C; Stein M; Hellstern P; Brass H
    Clin Nephrol; 1998 Mar; 49(3):186-92. PubMed ID: 9543601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron management in renal failure patients--how do we achieve the best results?
    Kosch M; Schaefer RM
    EDTNA ERCA J; 2002; 28(4):182-4. PubMed ID: 12638935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
    Besarab A; Dalton CL
    Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.